Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX) will attend and present at multiple investor conferences in November 2025, including corporate presentations and a fireside chat.

Scheduled events:

• Truist Securities BioPharma Symposium — Nov 6, 2025 at 10:40am ET, Lotte New York Palace Hotel, New York City.
• HC Wainwright Emerging Ideas on BioPharma — Nov 7, 2025 at 12:30pm ET, fireside chat with analyst Doug Tsao (registration available).
• Guggenheim Securities Healthcare Innovation Conference — Nov 10, 2025 at 9:30am ET, InterContinental Boston; live webcast available.
• Jefferies Global Healthcare Conference — Nov 18, 2025 at 1:30pm GMT, Waldorf Hilton London; live webcast available.

Replays of the third quarter earnings webinar and conference webcasts will be posted on Praxis’ Events and Presentations page for approximately 90 days after each event.

Praxis Precision Medicines (NASDAQ: PRAX) reported positive Phase 3 results for ulixacaltamide in essential tremor (Essential3), with Study 1 showing a 4.3-point mean mADL11 improvement at Week 8 (p<0.0001) and Study 2 showing 55% vs 33% maintained response (p=0.037). A pre-NDA meeting with FDA is scheduled for Q4 2025. Praxis plans an interim EMBOLD analysis for relutrigine in Q4 2025 that could support an NDA in early 2026. Vormatrigine POWER1 recruitment is complete with topline readout expected 1H 2026. Pro forma cash and investments are ~$956M, expected to fund operations into 2028.

Praxis (NASDAQ: PRAX) said it reached alignment with the FDA after a Type B meeting and written advice on the protocol and SAP for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA agreed Praxis’ planned interim analysis of the EMBOLD cohort 2 study, scheduled for Q4 2025, may serve as the basis for an NDA submission in early 2026 if positive. The interim will use ~70% of 16-week study patients and is controlled at a 4% alpha; a negative interim would preserve a final analysis at 1% alpha (n≈80). Prior EMBOLD cohort 1 results showed an ANCOVA p-value of 0.0354 for seizure reduction versus placebo. Praxis also opened enrollment in the registrational EMERALD trial in Q3 2025, with completion expected in H2 2026.

Praxis Precision Medicines (NASDAQ: PRAX) priced an underwritten public offering to raise approximately $525 million gross by issuing 3,025,480 shares of common stock at $157.00 per share and pre-funded warrants to buy up to 318,470 shares at $156.9999 each.

The company granted underwriters a 30-day option to purchase up to 501,592 additional shares. The offering is expected to close on or about October 20, 2025, subject to market conditions and customary closing conditions.

Praxis Precision Medicines (NASDAQ: PRAX) announced a proposed public offering of its common stock and, for certain investors, prefunded warrants to buy common stock. The company said all offered securities will be sold by Praxis and underwriters have a 30-day option to buy additional shares up to 15% of the offering. TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are joint book-running managers. The offering is made from a shelf registration that became effective on Dec 23, 2024 and is subject to market and customary closing conditions. Final terms will appear in a prospectus supplement; the release is not an offer to sell securities.

Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline Phase 3 results for ulixacaltamide in the Essential3 program for essential tremor (ET) on October 16, 2025. In Study 1 (parallel-group) ulixacaltamide produced a mean Modified Activities of Daily Living-11 improvement of 4.3 points at Week 8 (p<0.0001) and all key secondaries were statistically significant (p<0.001). Study 2 (randomized-withdrawal) met its primary endpoint (maintenance of effect, p=0.0369) and a key secondary (rate of improvement, p=0.0042). The drug was generally well tolerated with no drug-related serious adverse events. Praxis has requested a pre-NDA meeting with the FDA and will host an investor call on October 16, 2025.

Praxis Precision Medicines (Nasdaq: PRAX) announced on October 1, 2025 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 4,200 shares to three new non‑executive employees under the 2024 Inducement Plan.

The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to the recipients' continued employment on each vesting date. The 2024 Inducement Plan is reserved exclusively for equity awards to newly hired individuals or those returning after a bona fide break in service.

ReCode Therapeutics has secured over $29 million in additional financing to advance its genetic medicines pipeline. The company received $3 million in new funding from the Cystic Fibrosis Foundation, bringing the Foundation's total potential investment to $33 million for mRNA and gene editing research programs.

The company announced a research collaboration with Praxis Precision Medicines (NASDAQ: PRAX) to develop lipid nanoparticle formulations for ASO delivery to the brain. ReCode's lead program, RCT2100, an inhaled mRNA therapy for cystic fibrosis, is currently in Phase 2 clinical trials, aiming to benefit all CF patients, including those with rare and nonsense mutations.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in September 2025:

• Baird Global Healthcare Conference - Corporate presentation on September 9th at 9:00 AM EDT
• H.C. Wainwright Global Investment Conference - Fireside chat on September 10th at 8:30 AM EDT
• TD Cowen Novel Mechanisms Summit - Virtual presentation on September 18th at 3:00 PM EDT

One-on-one meetings will be available at all events, and webcasted presentations will be accessible through the company's website for 90 days.